

APR 1 3 2009

Attorney Docket No. 1830.1025

N THE UNITED STATES PATENT AND TRADEMARK OFFICE

PADENN	IN THE UNITED STATES PATENT	AND TRADEINARY OFFICE
In re Patent Ap	oplication of:	
Naoaki YAMA	SAKI et al.	
Application No	.: 10/587,827	Group Art Unit: 1616
Confirmation I	lo. 2378	
Filed: July 28	2006	Examiner: Nathan W. Schlientz
	US CELLULOSE AGGREGATE AND RISING THE SAME	FORMED PRODUCT COMPOSITION
	INFORMATION DISCLO	SURE STATEMENT
Commissioner PO Box 1450 Alexandria, VA		
Sir:		
provided certa subject U.S. p	in information which the Examiner m	ovisions of 37 CFR § 1.56, there is hereby ay consider material to the examination of the the Examiner make this information of record bject application.
1. Enclos	ures accompanying this Information	Disclosure Statement are:
	Application publications.	ccept for U.S. Patents and U.S. Patent mmunication(s) from a foreign Patent Office
1d.	or a PCT International Search English language translation (
1e. 1f. 1g.	Explanations of Relevancy of providing a concise explanationList of Copending Applications	
2. This Information Disclosure Statement is filed under 37 CFR § 1.97(b): (Check either Item 2a or 2b or 2c or 2d)		
2a. 2b.	Within three months of the dat § 1.491 in an international app	
2c. 2d.		fice Action after the filing of a Request for

Serial No.: 10/587,827

3.		This Information Disclosure Statement is filed under 37 CFR § 1.97(c) after the period specified in paragraph 2 above but before the mailing date of any of a Final Office Action under § 1.113, a Notice of Allowance under § 1.311 or an action that otherwise closes prosecution in the application, AND		
	٠		(Check either Item 3a or 3b; Item 3b to be checked if any reference known for more than 3 months)	
		3a. 🗌 3b. 🔲	The § 1.97(e) Statement in Item 5 below is applicable; OR The \$180.00 fee set forth in 37 CFR § 1.17(p) is: enclosed.	
			to be charged to Deposit Account No. 19-3935.	
4.			mation Disclosure Statement is filed under 37 CFR § 1.97(d) after the period in paragraph 3 above, but on or before payment of the Issue Fee, AND	
		4a. 🗌 4b. 🔲	The § 1.97(e) Statement in Item 5 below is applicable; AND The \$180.00 fee set forth in 37 CFR § 1.17(p) is: enclosed.	
			to be charged to Deposit Account No. 19-3935.	
5.		Statemen	t under § 1.97(e) (applicable if Item 3a or Item 4a is checked) (Check either Item 5a or 5b)	
		5a. 🗌	In accordance with 37 CFR § 1.97(e)(1), it is stated that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.	
		5b.	In accordance with 37 CFR § 1.97(e)(2), it is stated that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known by any individual designated in § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.	
6.		This is a (continuation/divisional/continuation-in-part application under 37 CFR §	
			(Check appropriate Items 6a and/or 6b)	
		6a. 🗌	Copies of the publications listed on the attached Form PTO-1449 which were previously cited in prior application Serial No, filed on, and which is relied on for an earlier effective filing date for the subject application under 35 U.S.C. § 120, have been omitted pursuant to 37 CFR §	
		6b. 🗌	1.98(d). Copies of the publications listed on the attached Form PTO-1449 which were not previously cited in prior application Serial No, filed on, and which is relied on for an earlier effective filing date for the subject application under 35 U.S.C. § 120, are provided herewith.	

Serial No.: 10/587,827

7.		Request for Continued Examination under 37 CFR § 1.114.
		(Check either Item 7a or 7b)
	7a. 🗌 7b. 🗍	The Issue Fee has not been paid. A Petition to Withdraw from issue under 37 CFR § 1.313(c) is filed concurrently herewith or has been granted. A Request for Continued Examination under 37 CFR § 1.114, after payment of the Issue Fee, is proper in accordance with 37 CFR § 1.114(a), respectively.
8.	☐ This is a	Supplemental Information Disclosure Statement.
	_	(Check either Item 8a or 8b)
	8a. 🗌	This Supplemental Information Disclosure Statement under 37 CFR § 1.97(f) supplements the Information Disclosure Statement filed on A bona fide attempt was made to comply with 37 CFR § 1.98, but inadvertent omissions were made. These omissions have been corrected herein. Accordingly, additional time is requested so that this Supplemental IDS can be considered as if properly filed on
	8b. 🗌	This Supplemental Information Disclosure Statement is timely filed within one (1) month of the Notice under 37 CFR §§ 1.97 and 1.98, mailed
9.		ance with 37 CFR § 1.98, a concise explanation of what is presently d to be the relevance of each non-English language publication is:
		(Check appropriate Items 9a, 9b, 9c and/or 9d)
	9a. ☐ 9b. ☐	satisfied for the non-English language publication(s) cited on the enclosed "English language version of the search report or action which indicates the degree of relevance found by the foreign office". (See MPEP § 609, Minimum Requirements for an Information Disclosure Statement, Part A(3): Concise Explanation of Relevance, 8th Ed., Rev. 2) set forth in the application.
	9c.	satisfied for the non-English language publication(s) indicated on the attached Form PTO-1449 as having an English language translation
	9d. 🗌	(complete or relevant portion(s)) attached thereto. enclosed as Attachment 1(e), hereto.
10.	be, materia search rep	on is made that the information cited in this Statement is, or is considered to all to patentability nor a representation that a search has been made (other than ort(s) from a counterpart foreign application or a PCT International Search ubmitted herewith). 37 CFR §§ 1.97(g) and (h).

Serial No.: 10/587,827

11. The Commissioner is authorized to credit any overpayment or charge any additional fee required under 37 CFR § 1.17 for this Information Disclosure Statement to Deposit Account No. 19-3935.

Respectfully submitted,

STAAS & HALSEY LLP

Registration No. 36,162

Dated: 10 p 13 2001 1201 New York Ave., N.W., 7th Floor

Washington, D.C. 20005 Telephone: (202) 434-1500 Facsimile: (202) 434-1501

Revised January, 2005